J. M. Birch, F. P. Li, J. E. Garber, and D. A. Haber. 1999. Heterozygous 29.
germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 286:2528–
2531.
4. Bischoff, F. Z., S. O. Yim, S. Pathak, G. Grant, M. J. Siciliano, B. C.
Giovanella, L. C. Strong, and M. A. Tainsky. 1990. Spontaneous abnormal- 30.
ities in normal fibroblasts from patients with Li-Fraumeni cancer syndrome:
aneuploidy and immortalization. Cancer Res. 50:7979–7984.
5. Bouck, N., V. Stellmach, and S. C. Hsu. 1996. How tumors become angio- 31.
genic. Adv. Cancer Res. 69:135–174.
6. Bouffler, S. D., C. J. Kemp, A. Balmain, and R. Cox. 1995. Spontaneous and
ionizing radiation-induced chromosomal abnormalities in p53-deficient 32.
mice. Cancer Res. 55:3883–3889. 33.
7. Brugarolas, J., C. Chandrasekaran, J. I. Gordon, D. Beach, T. Jacks, and
G. J. Hannon. 1995. Radiation-induced cell cycle arrest compromised by p21
deficiency. Nature 377:552–557.
8. Burns, P. A., C. J. Kemp, J. V. Gannon, D. P. Lane, R. Bremner, and A. 34.
Balmain. 1991. Loss of heterozygosity and mutational alterations of the p53
gene in the skin tumors of interspecific hybrid mice. Oncogene 6:2363–2369. 35.
9. Chehab, N. H., A. Malikzay, M. Appel, and T. D. Halazonetis. 2000. Chk2/
hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. 36.
Genes Dev. 14:278–288.
10. Chen, J., K. Neilson, and T. Van Dyke. 1989. Lymphotropic papovavirus 37.
early region is specifically regulated in transgenic mice and efficiently induces
neoplasia. J. Virol. 63:2204–2214.
11. Chen, J., and T. Van Dyke. 1991. Uniform cell-autonomous tumorigenesis of 38.
the choroid plexus by papovavirus large T antigens. Mol. Cell. Biol. 11:5968–
5976.
12. Dameron, K. M., O. V. Volpert, M. A. Tainsky, and N. Bouck. 1994. Control 39.
of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265:1582–1584.
13. Debbas, M., and E. White. 1993. Wild-type p53 mediates apoptosis by E1A, 40.
which is inhibited by E1B. Genes Dev. 7:546–554.
14. Deng, C., P. Zhang, J. W. Harper, S. J. Elledge, and P. Leder. 1995. Mice 41.
lacking p21CIP/WAF1 undergo normal development, but are defective in
G1 checkpoint control. Cell 82:675–684.
15. Di Leonardo, A., S. H. Khan, S. P. Linke, V. Greco, G. Seidita, and G. M. 42.
Wahl. 1997. DNA rereplication in the presence of mitotic spindle inhibitors
in human and mouse fibroblasts lacking either p53 or pRb function. Cancer
Res. 57:1013–1019. 43.
16. Donehower, L. A., L. A. Godley, C. M. Aldaz, R. Pyle, Y. P. Shi, D. Pinkel, J.
Gray, A. Bradley, D. Medina, and H. E. Varmus. 1995. Deficiency of p53
accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes
chromosomal instability. Genes Dev. 9:882–895.
17. Donehower, L. A., M. Harvey, B. L. Slagle, M. J. McArthur, C. A. J. Mont- 44.
gomery, J. S. Butel, and A. Bradley. 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356:215–
221.
18. Filatov, L., V. Golubovskaya, J. C. Hurt, L. L. Byrd, J. M. Phillips, and W. K. 45.
Kaufmann. 1998. Chromosomal instability is correlated with telomere erosion and inactivation of G2 checkpoint function in human fibroblasts ex- pressing human papillomavirus type 16 E6 oncoprotein. Oncogene 16:1825– 46.
1838.
19. Forozan, F., R. Karhu, J. Kononen, A. Kallioniemi, and O. Kallioniemi.
1997. Genome screening by comparative genomic hybridization. Trends 47.
Genet. 13:405–409.
20. Fukasawa, K., T. Choi, R. Kuriyama, S. Rulong, and G. F. Vande Voude.
1996. Abnormal centrosome amplification in the absence of p53. Science 48.
271:1744–1747.
21. Fukasawa, K., F. Wiener, G. F. Vande Woude, and S. Mai. 1997. Genomic
instability and apoptosis are frequent in p53 deficient young mice. Oncogene 49.
15:1295–1302.
22. Hansen, R., and M. Oren. 1997. p53; from inductive signal to cellular effect.
Curr. Opin. Genet. Dev. 7:46–51. 50.
23. Hartwell, L. H., and M. B. Kastan. 1994. Cell cycle control and cancer. 51.
Science 266:1821–1828.
24. Harvey, M., A. T. Sands, R. S. Weiss, M. E. Hegi, R. W. Wiseman, P.
Pantazis, B. C. Giovanella, M. A. Tainsky, A. Bradley, and L. A. Donehower.
1993. In vitro growth characteristics of embryo fibroblasts isolated from 52.
p53-deficient mice. Oncogene 8:2457–2467.
25. Hermeking, H., C. Lengauer, K. Polyak, T. C. He, L. Zhang, S. Thiagalingam, K. W. Kinzler, and B. Vogelstein. 1997. 14-3-3 sigma is a p53- 53.
regulated inhibitor of G2/M progression. Mol. Cell 1:3–11.
26. Hirao, A., Y. Y. Kong, S. Matsuoka, A. Wakeham, J. Ruland, H. Yoshida, D.
Liu, S. J. Elledge, and T. W. Mak. 2000. DNA damage-induced activation of 54.
p53 by the checkpoint kinase Chk2. Science 287:1824–1827.
27. Hollstein, M., B. Shomer, M. Greenblatt, T. Soussi, E. Hovig, R. Montesano,
and C. C. Harris. 1996. Somatic point mutations in the p53 gene of human
tumors and cell lines: updated compilation. Nucleic Acids Res. 24:141–146. 55.
28. Howes, K. A., N. Ransom, D. S. Papermaster, J. G. H. Lasudry, D. M. Albert,
and J. J. Windle. 1994. Apoptosis or retinoblastoma: alternative fates of
photoreceptors expressing the HPV-16 E7 gene in the presence or absence 56.
of p53. Genes Dev. 8:1300–1310.
